MHMalik Salman Haider

Malik Salman Haider

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Malik Salman Haider has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Philipp Stahlhut

    4 shared publications
  • Arun Kumar Mahato

    Laboratory of Molecular Neuroscience, Institute of Biotechnology, HiLIFE, University of Helsinki, 00014Helsinki, Finland

    3 shared publications
  • Bettina Böttcher

    Biocenter and Rudolf Virchow Centre, Julius-Maximilians-University Würzburg, Haus D15, Josef-Schneider-Strasse 2, 97080Würzburg, Germany

    3 shared publications
  • Jost Hillenkamp

    University Hospital Würzburg Josef-Schneider-Str. 11

    3 shared publications
  • Robert Luxenhofer

    Soft Matter Chemistry, Department of Chemistry, and Helsinki Institute of Sustainability Science, Faculty of Science, University of Helsinki, PB 55, 00014 Helsinki, Finland

    3 shared publications
  • Stefan Forster

    Functional Polymer Materials, Chair for Advanced Materials Synthesis, Institute for Functional Materials and Biofabrication, Department of Chemistry and Pharmacy, Julius-Maximilians-University Würzburg, Röntgenring 11, 97070Würzburg, Germany

    3 shared publications

Latest Publications

  • Poly(2-oxazoline)- and Poly(2-oxazine)-Based Formulation Library Reveals Limits of Solubility Parameter-Based Drug-Polymer Compatibility Prediction

    by Malik Salman Haider, Robert Luxenhofer

    Four structurally related poly(2-oxazoline) (POx)- and poly(2-oxazine) (POzi)-based ABA triblock copolymers were evaluated across 21 poorly water-soluble drugs to assess whether Hansen solubility parameters (HSPs) predict polymer-specific formulation performance. HSPs were calculated using Hoftyzer-Van Krevelen (HnV) and Yamamoto molecular break (YMB) methods, with semi-empirical polymer HSPs derived from solvent−solubility profiles. The polymers showed drug-specific performance, with maximum loading capacities exceeding 40 wt % for four drugs and 30 wt % for another four drugs. However, Ra showed limited discriminatory power. Among 20 drugs with YMB-derived Ra values, the lowest-Ra polymer was experimentally best for only 4 (20%), while Ra-based and experimental within-drug pairwise rankings agreed in 59 of 119 comparisons (49.6%). Significant cross-drug correlations for two polymers were positive, opposite to the expected trend. Despite this limited predictive performance, the resulting formulation library provides a broad experimental platform for identifying polymer-drug combinations for subsequent application-specific preclinical development.

  • High-Capacity Dexamethasone-Loaded Poly(2-Oxazoline) Micelles for Ocular Surface Applications

    by Raoul Verma-Fuehring, Martina Wiesler, Upeka Obeysekara, Vanessa J Flegler, Bettina BötTcher, Daniel Kampik, Jost Hillenkamp, Malik Salman Haider

    The clinical efficacy of dexamethasone (DEX) in ocular therapy remains limited by its low aqueous solubility and restricted epithelial permeability. To address these limitations, we developed high-capacity micellar formulations by a modified thin-film hydration method utilizing two poly(2-oxazoline) (POx)-based ABA triblock copolymers (A-pBuOx-A and A-pPentOx-A). We achieved drug loading capacities of up to 33 wt.%. The DEX loaded nanoformulations were characterized by differential scanning calorimetry and powder X-ray diffraction confirming the amorphous nature of DEX in lyophilized formulations. The micelles had a hydrodynamic diameter of Dh ≈ 18−24 nm. Both polymers were well tolerated and did not show any toxicity in primary human conjunctival fibroblasts and epithelial cells up to 50 g/L. Furthermore, the A-pBuOx-A/DEX formulation increased the apparent permeability of DEX approximately 12.2-fold across a primary human conjunctival epithelial barrier compared with Dexa EDO, without evidence of compromised barrier integrity or cell viability. These findings establish the POx polymer platform as a promising approach for enhancing epithelial delivery of poorly water-soluble ophthalmic drugs.

  • Open Access

    A high-throughput 3D conjunctival spheroid model for standardized in vitro testing

    by Zhi Liang, Muhammad Aslam, Wahaj Ul Haq, Martina Wiesler, Su Naz Mutlu, Philipp Stahlhut, Raoul Verma-Fuehring, Ingrid Zahn, Friedrich P. Paulsen, Jürgen Groll, et al.

    New Approach Methodologies (NAMs) based on human cells are increasingly needed to improve the physiological relevance, reproducibility, and ethical acceptability of preclinical ocular surface research. We developed a reproducible and scalable three-dimensional in vitro conjunctival spheroid model using primary human conjunctival epithelial cells and conjunctival fibroblasts as a human-relevant, scaffold-free test system. Agarose-based microwell arrays were fabricated via a combination of custom-made high-resolution 3D printing and polydimethylsiloxane (PDMS) replica molding, enabling the formation of uniform microwells suitable for spheroid culture and parallel production of size-controlled microtissues. Primary human conjunctival epithelial cells and fibroblasts were isolated from donor tissue obtained during routine ophthalmic surgeries and expanded under defined culture conditions. Fibroblast spheroids were first generated within agarose microwells at controlled seeding densities, resulting in stable and size-controlled aggregates. Subsequently, conjunctival epithelial cells were seeded onto pre-formed fibroblast spheroids to establish bilayered conjunctival spheroids that mimic native tissue organization. Spheroid development, morphology, and viability were systematically characterized using optical microscopy, live/dead assays, histological staining, immunofluorescence, and advanced imaging techniques including scanning electron microscopy (SEM), cryo-SEM, and transmission electron microscopy (TEM). Quantitative image analysis demonstrated consistent spheroid size and shape over time, while viability assays confirmed high cell survival. Histological and ultrastructural analyses revealed organized cellular architecture and extracellular matrix deposition, indicative of functional tissue-like constructs. By combining primary human cells, scaffold-free assembly, and microwell-based scalability, this platform contributes to the implementation of the 3Rs and provides a fit-for-purpose NAM for dry eye disease-related research, conjunctival inflammation studies, and early-stage preclinical compound testing.

  • From injury to recovery: investigating wound healing in a 3D tissue-engineered cornea equivalent

    by Nicola Knetzger, Ann-Katrin Regensburger, Annika Goy, Hong Han, Johanna Theuersbacher, Ioana-Sandra Tarau, Carla Cleve, Lukas Königer, Tamara Finger, Sabina Eibichova, et al.


  • Open Access

    Biological Activity In Vitro, Absorption, BBB Penetration, and Tolerability of Nanoformulation of BT44:RET Agonist with Disease-Modifying Potential for the Treatment of Neurodegeneration

    by Malik Salman Haider, Arun Kumar Mahato, Anastasiia Kotliarova, Stefan Forster, Bettina Böttcher, Philipp Stahlhut, Yulia Sidorova, Robert Luxenhofer

    BT44 is a novel, second-generation glial cell line-derived neurotropic factor mimetic with improved biological activity and is a lead compound for the treatment of neurodegenerative disorders. Like many other small molecules, it suffers from intrinsic poor aqueous solubility, posing significant hurdles at various levels for its preclinical development and clinical translation. Herein, we report a poly(2-oxazoline)s (POx)-based BT44 micellar nanoformulation with an ultrahigh drug-loading capacity of 47 wt %. The BT44 nanoformulation was comprehensively characterized by 1H NMR spectroscopy, differential scanning calorimetry (DSC), powder X-ray diffraction (XRD), dynamic light scattering (DLS), and cryo-transmission/scanning electron microscopy (cryo-TEM/SEM). The DSC, XRD, and redispersion studies collectively confirmed that the BT44 formulation can be stored as a lyophilized powder and can be redispersed upon need. The DLS suggested that the redispersed formulation is suitable for parenteral administration (Dh ≈ 70 nm). The cryo-TEM measurements showed the presence of wormlike structures in both the plain polymer and the BT44 formulation. The BT44 formulation retained biological activity in immortalized cells and in cultured dopamine neurons. The micellar nanoformulation of BT44 exhibited improved absorption (after subcutaneous injection) and blood-brain barrier (BBB) penetration, and no acute toxic effects in mice were observed. In conclusion, herein, we have developed an ultrahigh BT44-loaded aqueous injectable nanoformulation, which can be used to pave the way for its preclinical and clinical development for the management of neurodegenerative disorders.


  • Open Access

    Biological activity In vitro, absorption, BBB penetration and tolerability of nanoformulation of BT44, a RET agonist with disease-modifying potential for the treatment of neurodegeneration

    by Malik Salman Haider, Arun Kumar Mahato, Anastasiia Kotliarova, Stefan Forster, Bettina Böttcher, Philipp Stahlhut, Yulia Sidorova, Robert Luxenhofer

    BT44 is a novel, second generation glial cell line-derived neurotropic factor (GDNF) mimetic, with improved biological activity and a lead compound for the treatment of neurodegenerative disorders. Like many other small molecules, it suffers from intrinsic poor aqueous solubility, posing significant hurdles at various levels for its preclinical development and clinical translation. Herein, we report a poly(2-oxazoline)s (POx) based BT44 micellar nanoformulation with ultra-high drug loading capacity of 47 wt.%. The BT44 nanoformulation was comprehensively characterized by 1H-NMR spectroscopy, differential scanning calorimetry (DSC), powder X-ray diffraction (XRD), dynamic light scattering (DLS) and cryo-transmission/scanning electron microscopy (cryo-TEM/SEM). The DSC, XRD and redispersion studies collectively confirmed that the BT44 formulation can be stored as a lyophilized powder and can be redispersed upon need. The DLS suggested that the redispersed formulation is suitable for parenteral administration (Dh ≈ 70 nm). The cryo-TEM measurements showed the presence of worm-like structures both in plain polymer and BT44 formulation. The BT44 formulation retained biological activity in immortalized cells and in cultured dopamine neurons. The micellar nanoformulation of BT44 exhibited improved absorption (after subcutaneous injection) and blood-brain barrier (BBB) penetration and no acute toxic effects in mice were observed. In conclusion, herein, we have developed an ultra-high BT44 loaded aqueous injectable nanoformulation, which can be used to pave way for its preclinical and clinical development for the management of neurodegenerative disorders.

  • Open Access

    Development of Poly(2-oxazoline)s and poly(2-oxazine)s based formulation library and estimation of polymer/drug compatibility.

    by Malik Salman Haider, Robert Luxenhofer

    The main objective of this study is to formulate a library of difficult to solubilize drugs with four slightly different poly(2-oxazoline)s (POx) and poly(2-oxazine)s (POzi) based amphiphilic triblock copolymers and to elucidate whether the drug-polymer compatibility, as estimated by solubility parameters (SPs) might be used as tool to guide formulation development. The theoretical and experimental SPs of different homo-/triblock copolymers and 21 different hydrophobic drugs were calculated by two group contribution methods (i.e. Hoftyzer Van-Krevelen and Yamamoto molecular break method) and determined experimentally by solubility testing in list of selective solvents (for polymers only). The obtained SPs were further utilized to calculate the distance between polymers and drugs (Ra) in 3 dimensional Hansen space. Out of 21 structurally diverse drugs, the loading capacity (LC) was found to be higher than 40, 30, 20 and 10 wt.% for 4, 4, 3 and 5 drugs, respectively. In the remaining of 5 drugs the maximum achievable LC was found below 10 wt.%. The experimental results obtained by formulation development were not in accordance with the results predicted by Ra calculation. In contrast to several reports found in the literature, the determination of SPs and concurrent compatibility estimation appeared not to be a suitable tool to predict polymer-drug compatibility in the present system. As the predictive power of SPs is based on simple mathematical calculations, limiting the precise prediction of overall polarity, hydrogen bonding ability of molecules and interplay between the hydrophilic and hydrophobic domains resulting in differing deviations than predicted interactions thus might compromise the predictive power of HSPs.


  • Open Access

    Biological activity In vitro, absorption, BBB penetration and toxicity of nanoformulation of BT44, a RET agonist with disease-modifying potential for the treatment of neurodegeneration

    by Malik Salman Haider, Arun Kumar Mahato, Anastasiia Kotliarova, Stefan Forster, Bettina Böttcher, Philipp Stahlhut, Yulia Sidorova, Robert Luxenhofer

    BT44 is a novel, second generation glial cell line-derived neurotropic factor (GDNF) mimetic, with improved biological activity and a lead compound for the treatment of neurodegenerative disorders. Like many other small molecules, it suffers from intrinsic poor aqueous solubility, posing significant hurdles at various levels for its preclinical development and clinical translation. Herein, we report a novel poly(2-oxazoline)s (POx) based BT44 micellar nanoformulation with ultra-high drug loading capacity of 47 wt.%. The BT44 nanoformulations were comprehensively characterized by 1H-NMR spectroscopy, differential scanning calorimetry (DSC), powder X-ray diffraction (XRD), dynamic light scattering (DLS) and cryo-transmission/scanning electron microscopy (cryo-TEM/SEM). The DSC, XRD and redispersion studies collectively confirmed that the BT44 formulation can be stored as a lyophilized powder and can be redispersed when needed. The DLS further suggested that the redispersed formulation is suitable for parenteral administration (Dh ≈ 70nm). The cryo-TEM analysis revealed the presences of worm like structures. The BT44 formulation retains biological activity in immortalized cells and in cultured dopamine neurons. The micellar formulation of BT44 exhibited improved absorption and blood-brain barrier (BBB) penetration and produced no acute toxic effects in mice. In conclusion, herein, we have developed an ultra-high BT44 loaded aqueous injectable nanoformulation, which can be used to pave way for its preclinical and clinical development for the management of neurodegenerative disorders.